

Becoming a Leader in Cancer Genetics and Precision Oncology

Prenetics' acquisition of ACT Genomics

December 2022



Prenetics™

NASDAQ: PRE

**Building the world's first end-to-end
health ecosystem for consumer and
clinical health**

Who is Prenetics

Our Goal


Build the world's **first end-to-end health ecosystem**

Decentralize healthcare by placing **online and offline clinical care** in your control, across **consumer health, medical and cancer genomics**

Key Milestones

- ✓ Leading Covid-19 testing provider, performing over 26 million Covid-19 tests to date. Daily average of 20,000 PCR tests
- ✓ Successfully listed on NASDAQ under ticker PRE in May 2022
- ✓ Transitioning from a Covid-19 player into an end-to-end solution provider in:
 - Consumer Health – Circle DNA, Circle Snapshot
 - Clinical Care – Telehealth, Primary care clinics
 - Medical and Cancer Genomics – Circle Medical, Coloclear
- ✓ Increased FY 22 Revenue Guidance to US \$270-280 million and Adjusted EBITDA to US \$47-53 million
- ✓ Maintains strong balance sheet with US\$230 million in cash & receivables
- ✓ Active discussions on additional M & A targets accretive to Prenetics and to shareholders

Our Vision



Prenetics™



**Our acquisition of ACT Genomics puts us
one step closer to our mission.**

Two genomics power-houses joining forces

Prenetics™

Democratize healthcare by building world's first end-to-end health ecosystem


- Leading genomic and diagnostic testing provider listed on NASDAQ under ticker PRE in May 2022
- Proven ability to execute at scale, having performed more than 26 million Covid-19 tests to date, with daily throughput at more than 40,000 tests
- In-house R&D developed suite of NGS products across consumer health, medical and cancer genomics (CircleDNA, ColoClear)
- Strong commercialization capabilities backed by strong relationships with insurers and healthcare providers
- Continuous financial strength – estimated US\$270 - \$280 million revenue in 2022
- Strong cash and receivables position of US\$230 million, allowing further investment in R & D for early detection

 **ACG GENOMICS®**

Integrated solution company for precision cancer management

- Strong IP with product portfolio across cancer prevention, treatment and disease monitoring
- World class and accomplished scientific team, including Professor Tony Mok, Dr Hua-Chien Chen, Dr Shu-Jen Chen
- Specimen types includes blood, tumor tissue and liquid biopsy
- 30,000+ clinical tests performed across Asia
- 200+ collaborating hospitals, 900+ oncologists
- 55+ pharma and research partners
- 5 operating labs across Hong Kong, Taiwan, Thailand, and Japan (Joint venture with Canon Medical Systems)
- Projected US\$25 – 30 million revenue in 2023

Tapping into US\$80bn+ Global Market in Cancer Genomics




Note: Market Size based on Prenetics internal analysis

Next Generation Sequencing to be the standard of care for cancer

Cancer is a complex disease of the genome. Each case is unique – beginning with risk identification or a diagnosis of cancer, access to comprehensive genetic information provides a clear decision path, personalized therapy and the ability to monitor progress, transforming cancer care.

9.4 million cancer patients in Asia annually



Hereditary risk and cancer diagnosis

Germline profiling + polygenic risk scores

Guidelines

Prognosis and treatment optimization

Pharmacogenomics

Therapy selection & modulation (tissue / liquid)

Clinical decision support and cancer monitoring

Clinical decision support

Cancer monitoring

To become a leader in cancer genetics and precision oncology



A single platform offering full suite of products from consumer health to medical and cancer genomics for consumers, patients, insurers, hospitals, pharma & researchers



Join hands to form best-in-class R&D and clinical team, making Prenetics the research and commercialization partner of choice



Powered by Prenetics' commercial capabilities, facilitated by strong relationships with insurers and leading institutions



Pan-Asia presence and global infrastructure, brings cancer prevention and diagnostics to patients worldwide



Prenetics strong balance sheet allows for further R & D investment into liquid biopsy for early detection of Cancer

Prenetics™



Comprehensive cancer product panel adding to consumer DNA

Across cancer prevention, treatment and monitoring, comparable to leading US cancer genetic players

Designed for	Product	Platform	Sample type			Cancer type	Comparables
			Tissue	Blood	Liquid biopsy		
Treatment Selection	ACT Onco[®]+ (under FDA review)	NGS (400+ genes)	✓			Pan-cancer	Foundation Medicine (FoundationOne)
	ACT Drug[®]+	NGS	✓			Lung, Breast, Colon, Gastric	Thermo Fisher (OncoPrint)
	ACT Fusion[™]	NGS (RNA-based)	✓			Pan-cancer	Archer (FusionPlex)
	ACT HRD[™]	NGS	✓			Ovary, Breast, Prostate, Pancreas	Myriad (MyChoice)
	ACT BRCA[®]	NGS	✓			Ovary, Breast, Prostate, Pancreas	
	ACT Lung[™]	NGS	✓			Lung	
	RE[®]SNAP	NGS			✓	Lung	
	NCOSNAP Nonet	RT-PCR	✓			Lung	
	β-EGFR[®]	ddPCR			✓	Lung	
	ACT SPOT[™]	Genechip	✓			Pan-cancer	
Risk assessment	ACT Risk[™]	NGS		✓		Pan-cancer	Myriad (MyRisk)
	ACT BRCA[®]	NGS		✓		Ovary, Breast, Prostate, Pancreas	Myriad (BRCA Analysis)
Disease monitor	ACT Monitor[®]+	NGS			✓	Pan-cancer	Guardant Health (Guardant 360)

Supported by patient stories...

One of the benefits of ACT Genomics' profiling is to help with early detection of genetic mutations that are one of the culprits of liver cancer. If liver cancer does recur or there is development of a secondary cancer, genomic profiling will help the doctors to detect it early and to understand the genetic makeup of the tumor. The analysis was performed using the **ACTMonitor®+ sequencing panel which detects hotspot mutations in 50 genes**... To date I have done three rounds of ACTMonitor®+ profiling to monitor the mutations of my liver tumor semi-annually.

Dr Andrew Tay, Liver cancer patient

Cancer treatment for patients with metastasized cancer would rely on doctors on what kind of medicine to prescribe to patients... if first line of medicine fails, they would move on to try other types of medication... precision medicine is to undergo cancer genomic profiling before treatment begins, so that doctors understand side effects for a patient from a type of medicine... formulate most effective medication for patient... Ms Chang underwent cancer profiling using **ACTMonitor®+ to test blood for cancer monitoring and ACTOnco®+ to test cancer tissue for the right treatment options**

Ms Chang, Ovarian cancer patient

Considering my mother was too old to endure continual surgeries for the case of recurrence, after discussion with Dr. Ma, we decided to use an immune checkpoint inhibitor. Luckily, her tumor shrank a lot without skin secretion and she began returning to her normal weight. The results from the half yearly MRI scans have been normal, and we have also undertaken **ACTOnco®+ test to search for more treatment options in case of recurrence. The ACTOnco®+ test confirmed that my mother's cancer cells would have a high response rate to immunotherapy.**

Ms Chen, Skin cancer patient

It is my belief that the services from ACT Genomics have provided information that support cancer molecular diagnostics which greatly benefit our cancer patients

Bumrungrad Hospital

... heartfelt thanks and appreciation for introducing the all-comprehensive **ACTOnco®+** to me in the past year. ... so far on **clinical difficult cases have provided very useful information and guidance on choosing subsequent target / immunotherapy.**

Specialist in clinical oncology

Best-in-class R&D and clinical team

Prenetics™



Lawrence Tzang, PhD
Chief Scientific Officer &
Co-Founder



Dr. Senthil Sundaram, M.D.
Chief Clinical Officer



Mike Ma, PhD
Chief R&D Officer



Frank Ong, MD
Chief Medical Officer



Prof. Zhanfeng Cui
Donald Pollock Professor
of Chemical Engineering,
University of Oxford



Prof. Wei Huang
Associate Professor in
Dept. of Engineering
Science,
University of Oxford



Dr. Monique Andersson
Medical Advisor,
Director of Microbiology,
Oxford University Hospitals,
NHS Foundation Trusts



Prof. Michael Yang
Chair Professor of Biomedical
Sciences, Vice-President
(R&D) City University of
Hong Kong



Professor Tony Mok
Chairman



Hua-Chien Chen, PhD
Chief Executive Officer



Shu-Jen Chen, PhD
Chief Scientific Officer



Dr. Kristy Lee
Chief Medical Officer



Pan-Asia presence and extensive customer and partner portfolio further strengthened by Prenetics' commercialization capabilities

200+ collaborating hospitals, 900+ oncologists



55+ biopharma and research partners



Prenetics' long term insurers and healthcare partners



- ✓ 30,000+ clinical tests performed across Asia
- ✓ 4 CAP accredited labs and operations spanning across Hong Kong, Taiwan, Japan, Singapore, Thailand, United Kingdom



Transaction overview

TERMS	<ul style="list-style-type: none">• Prenetics acquires a majority stake in ACT Genomics (“ACT”)• Cash consideration of US\$20 million• 19.9 million shares of Prenetics common stock
FINANCIAL BENEFITS	<ul style="list-style-type: none">• ACT projected \$25-30 million revenue in 2023• Target to achieve break-even by end of 2023• Significant further upside with reimbursements and insurance
SYNERGIES	<ul style="list-style-type: none">• Immediate addition of cancer genetics and precision oncology tests to complement Prenetics’ existing consumer DNA testing and medical genomics product portfolio• Streamline operating expenses, Prenetics’ infrastructure support on various center of excellence aspects (e.g. sales and marketing, product design and management, information technology and laboratory)